PMID- 22036896
OWN - NLM
STAT- MEDLINE
DCOM- 20120320
LR  - 20220408
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 2
IP  - 10
DP  - 2011 Oct
TI  - Systemic use of tumor necrosis factor alpha as an anticancer agent.
PG  - 739-51
AB  - Tumor necrosis factor-alpha (TNF-alpha) has been discussed as a potential anticancer 
      agent for many years, however initial enthusiasm about its clinical use as a 
      systemic agent was curbed due to significant toxicities and lack of efficacy. 
      Combination of TNF-alpha with chemotherapy in the setting of hyperthermic isolated 
      limb perfusion (ILP), has provided new insights into a potential therapeutic role 
      of this agent. The therapeutic benefit from TNF-alpha in ILP is thought to be not 
      only due to its direct anti-proliferative effect, but also due to its ability to 
      increase penetration of the chemotherapeutic agents into the tumor tissue. New 
      concepts for the use of TNF-alpha as a facilitator rather than as a direct actor are 
      currently being explored with the goal to exploit the ability of this agent to 
      increase drug delivery and to simultaneously reduce systemic toxicity. This 
      review article provides a comprehensive overview on the published previous 
      experience with systemic TNF-alpha. Data from 18 phase I and 10 phase II single agent 
      as well as 18 combination therapy studies illustrate previously used treatment 
      and dose schedules, response data as well as the most prominently observed 
      adverse effects. Also discussed, based on recent preclinical data, is a potential 
      future role of systemic TNF-alpha in combination with liposomal chemotherapy to 
      facilitate increased drug uptake into tumors.
FAU - Roberts, Nicholas J
AU  - Roberts NJ
AD  - Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel 
      Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD 21231, 
      USA.
FAU - Zhou, Shibin
AU  - Zhou S
FAU - Diaz, Luis A Jr
AU  - Diaz LA Jr
FAU - Holdhoff, Matthias
AU  - Holdhoff M
LA  - eng
GR  - P50 CA062924/CA/NCI NIH HHS/United States
GR  - R01 CA129825/CA/NCI NIH HHS/United States
GR  - CA129825/CA/NCI NIH HHS/United States
GR  - CA062924/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*therapeutic use
PMC - PMC3248159
COIS- The authors declare no conflicts of interest.
EDAT- 2011/11/01 06:00
MHDA- 2012/03/21 06:00
PMCR- 2011/10/01
CRDT- 2011/11/01 06:00
PHST- 2011/11/01 06:00 [entrez]
PHST- 2011/11/01 06:00 [pubmed]
PHST- 2012/03/21 06:00 [medline]
PHST- 2011/10/01 00:00 [pmc-release]
AID - 344 [pii]
AID - 10.18632/oncotarget.344 [doi]
PST - ppublish
SO  - Oncotarget. 2011 Oct;2(10):739-51. doi: 10.18632/oncotarget.344.